Bifogade filer
Kurs
+5,51%
Kalender
Tid* | ||
2025-08-21 | N/A | Årsstämma |
2025-05-08 | 20:30 | Bokslutskommuniké 2025 |
2025-02-05 | 07:00 | Kvartalsrapport 2025-Q3 |
2024-11-06 | - | Kvartalsrapport 2025-Q2 |
2024-08-20 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2024-08-19 | - | Årsstämma |
2024-08-08 | - | Kvartalsrapport 2025-Q1 |
2024-05-14 | - | Bokslutskommuniké 2024 |
2024-02-14 | - | Kvartalsrapport 2024-Q3 |
2023-11-17 | - | Kvartalsrapport 2024-Q2 |
2023-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2023-08-17 | - | Årsstämma |
2023-08-16 | - | Kvartalsrapport 2024-Q1 |
2023-05-11 | - | Bokslutskommuniké 2023 |
2023-02-14 | - | Kvartalsrapport 2023-Q3 |
2023-02-13 | - | Kvartalsrapport 2023-Q3 |
2022-11-11 | - | Kvartalsrapport 2023-Q2 |
2022-10-26 | - | Extra Bolagsstämma 2022 |
2022-08-18 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2022-08-17 | - | Årsstämma |
2022-08-16 | - | Kvartalsrapport 2023-Q1 |
2022-05-13 | - | Bokslutskommuniké 2022 |
2022-02-16 | - | Kvartalsrapport 2022-Q3 |
2021-11-11 | - | Kvartalsrapport 2022-Q2 |
2021-08-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2021-08-18 | - | Årsstämma |
2021-08-18 | - | Kvartalsrapport 2022-Q1 |
2021-05-06 | - | Bokslutskommuniké 2021 |
2021-02-18 | - | Kvartalsrapport 2021-Q3 |
2020-11-06 | - | Kvartalsrapport 2021-Q2 |
2020-08-28 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2020-08-27 | - | Årsstämma |
2020-08-27 | - | Kvartalsrapport 2021-Q1 |
2020-05-04 | - | Bokslutskommuniké 2020 |
2020-02-05 | - | Kvartalsrapport 2020-Q3 |
2019-11-11 | - | Kvartalsrapport 2020-Q2 |
2019-08-23 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2019-08-22 | - | Årsstämma |
2019-08-22 | - | Kvartalsrapport 2020-Q1 |
2018-08-22 | - | Årsstämma |
2018-05-24 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2018-05-23 | - | Bokslutskommuniké 2018 |
2017-10-24 | - | Kvartalsrapport 2018-Q3 |
2017-08-21 | - | Kvartalsrapport 2018-Q2 |
2017-05-16 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2017-05-15 | - | Årsstämma |
2017-05-15 | - | Kvartalsrapport 2018-Q1 |
2017-02-08 | - | Bokslutskommuniké 2017 |
2016-10-25 | - | Kvartalsrapport 2017-Q3 |
2016-08-09 | - | Kvartalsrapport 2017-Q2 |
2016-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2016-05-13 | - | Årsstämma |
2016-05-13 | - | Kvartalsrapport 2017-Q1 |
2016-02-20 | - | Bokslutskommuniké 2016 |
2016-02-16 | - | Bokslutskommuniké 2016 |
2015-11-11 | - | Kvartalsrapport 2016-Q3 |
2015-10-09 | - | Extra Bolagsstämma 2016 |
2015-08-05 | - | Kvartalsrapport 2016-Q2 |
2015-05-19 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2015-05-18 | - | Årsstämma |
2015-05-18 | - | Kvartalsrapport 2016-Q1 |
2015-02-06 | - | Bokslutskommuniké 2015 |
2014-11-10 | - | Kvartalsrapport 2015-Q3 |
2014-08-13 | - | Extra Bolagsstämma 2015 |
2014-08-11 | - | Kvartalsrapport 2015-Q2 |
2014-05-13 | - | X-dag ordinarie utdelning EQL 0.00 SEK |
2014-05-12 | - | Årsstämma |
2014-05-12 | - | Kvartalsrapport 2015-Q1 |
2014-02-07 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
EQL Pharma's CEO, Axel Schörling, has increased his stake in the company. During the period 22-24 May, Axel Schörling has bought 53,903 shares in the Company at a volume-weighted average price of SEK 47.05, a transaction totalling SEK 2,536,010. The trades were made on Spotlight Stock Market. After the purchases, Schörling owns a total of 311,016 shares, which corresponds to 1.1% of the shares in the Company. This makes him EQL's 3rd largest physical owner and the 9th largest, institutions included.
"It feels absolutely right for me to increase my ownership in EQL," says Axel Schörling. "Many components are falling into place for us and I see a bright future ahead, which I now prove with actions, and not just words. To lead EQL Pharma is a great honour for me and an amazing adventure. To additionally, now be one of the largest owners, adds extra spice" Schörling concludes.
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com